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ABSTRACT
In this thesis muscular modifications in chronic spinal cord injured patients have been 
investigated. Using a translational approach, a mini-invasive muscular biopsy 
technique in Spinal Cord Injured patients has been validated. Moreover, the possible 
role of circulating levels of myostatin as  a possible candidate biomarker for muscular 
modifications in chronic SCI patients has been evaluated. Lastly, the molecular 
modifications of PGE2 pathway on muscular specimens of chronic SCI patients has 
been studied.
All material is original and based on direct Author ’s experience. 
RIASSUNTO
In questa tesi vengono indagate le modificazioni muscolo-scheletriche in pazienti 
affetti da mielolesione cronica. In un’ottica traslazionale, si è affrontata la 
problematica in oggetto partendo dalla validazione di una metodica di prelievo 
bioptico mini-invasivo muscolare su paziente, alla determinazione di un possibile 
biomarker serico di modficazione muscolare, la miostatina. Inoltre si è iniziato a 
investigare il ruolo del PGE2 come possibile mediatore delle modificazioni muscolo 
scheletriche nei pazienti mielolesi cronici.
Tutto il materiale è originale e basato sull’esperienza diretta dell’autore.
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ABBREVIATIONS
SCI: Spinal Cord Injury
TSCI: Traumatic Spinal Cord Injury
PG: Prostaglandins
PGE2: Prostaglandin E 2
COX: Cyclooxygenase
EP: Prostaglandind E recepor
CSA: Cross sectional area
LRP: Low-density lipoprotein receptor-related protein
25(OH)D: 25 hydroxy vitamin D
IGF-I: Insulin Growth Factor I
CRP: C reactive protein
BALP: Bone specific alkalyne phosphatase
CTX: Collagen Beta crosslaps
iCa: Ionized Calcium
P: Phosphorus
MRFs: Myogenic regulatory factors
TGF: Transforming growth factor
MCP: Muscular cells precursors
GPCRs: G protein coupled receptors
CNS: Central nervous system
LTB4: Leukotriene B4
eGFR: estimated glomerular filtration rate
PTH: parathyroid hormone
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INTRODUCTION
1 SPINAL CORD INJURY
1.1 DEFINITION
The term spinal cord injury (SCI) refers to any injury to the spinal cord that is caused 
by trauma instead of disease [1]. Depending on where the spinal cord and nerve 
roots  are damaged, the symptoms can vary widely, from pain to paralysis and 
incontinence [2-3]. Spinal cord injuries are described at various levels from 
"incomplete", which can vary from having no effect on the patient to a "complete" 
injury which means a total loss of function. 
Spinal cord injuries  are most often traumatic (TSCI), caused by lateral bending, 
dislocation, rotation, axial loading, and hyperflexion or hyperextension of the cord or 
cauda equina. Among the most common cause of SCIs are included: motor vehicle 
accidents, falls, work-related accidents, sports injuries, and penetrations such as stab 
or gunshot wounds [4]. SCIs  can also be of a non-traumatic origin, as in the case of 
cancer, infection, intervertebral disc disease, vertebral injury and spinal cord vascular 
disease [5].
1.2 EPIDEMIOLOGY
US Data
Epidemiological data about TSCI in the United States show a trend of increase of the 
age-adjusted incidence rate of this  pathology. Thus, from an incidence of 29.1 per 
8
million population in 1970 there has been a raise to 42.8 per million population in 
1977, according to the National Hospital Discharge Survey [6, 7].
This  positive trend has been confirmed also by more recent papers, showing an 
overall incidence of about 40 cases per million population per year and 12000 new 
cases per year with a total of 270000 TSCI survivors [8-10]. However these data 
suggest also an increase in mean age at injury ranging from 28.7 years in 1973-79 to 
40.2 in 2005-2009.
A recent paper showed a further increase in the overall incidence of TSCI of about 
56.4 per million adults over the study period, confirming also the previously increased 
age at the time of lesion with a mean value of 50.4 years [11]. Lastly, along with the 
raise of age the incidence reaches the dramatic value of 79.4 per million older adults 
in 2007 and 87.7 by the end of 2009, confirming the data previously obtained [11]. 
Moreover other data about complete/incomplete lesion, lesion etiology, rehabilitative 
setting and costs have been provided [11].
Italian Data
In Italy, the incidence of SCI is estimated, by surveys that are either retrospective or 
lack case mix, to be 18 to 20 per million [13-16]. 
Moreover, two large observational studies  in the last few years  addressed this issue. 
They were performed by the same group called GISEM (Gruppo Italiano Studio 
Epidemiologico Mielolesioni Study). They showed an increased incidence of SCI in 
men (a sex ratio of 4:1) and a rather low mean age compared to more recent studies 
previously carried on in the US (38.5 years). A total of 368 (53.8%) patients were 
involved in a road collision ( 36.8% of all from automobile collisions; 13.8% derived 
from motorcycle collisions. Falls accounted for 22.6% of the SCIs; sport injuries, 
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7.9%; weapon wounds, mainly from gunshots  that occurred during hunting rather 
than during episodes of violence, 1.9%; and attempted suicide, 4.3%. 
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2 SARCOPENIA and MUSCLE MODIFICATIONS IN NEUROLOGIC DISEASES
2.1 DEFINITION
The reduction of bone mass and consequent limitation in mobility observed in the 
elderly has been generally defined as Sarcopenia for the first time in 1989 [14]. This 
condition is common in the elderly, since the prevalence of muscle loss is  around 
20% under 70 years rising up to 40% over 80 years [15]. For this reason in the last 
two decades the interest of researchers in sarcopenia has grown widely [16]. 
However at the moment, despite its spread, making a correct diagnosis of sarcopenia 
is  quite difficult, due to the fact that in the last 20 years a wide range of definitions 
and diagnostic criteria have been proposed. Recently [17], there is general 
agreement on considering sarcopenia, in the old people, as a condition in which at 
least 2 of the following criteria apply: 1) low muscle mass (muscle mass ≥2 standard 
deviations below the mean of young subjects  aged 18-39 years as reported in the 
third NHANES study) [15]; 2) low muscle strength; 3) low physical performance 
(defined as a walking speed below 0.8 m/s in the 4-m walking test) [18].
It comes well evident that this definition, which has been proposed for elderly people, 
has some limitations in populations with neurologic disabilities, that can limit muscle 
strength and gait speed. Actually, a recent paper stated that in sarcopenia mobility 
reduction should not be a result of conditions as otherwise defined specific diseases 
of muscle, peripheral vascular disease with intermittent claudication, central and 
peripheral nervous system disorders, or cachexia [19].
So, defining sarcopenia in people with a limited mobility due to other diseases (as 
chronic neurologic diseases) can be puzzling. This is the main reason for which 
paretic limb has 20% less  mass than the non affected side, and the intramuscular fat 
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was significantly increased. Moreover, the amount of intramuscular fat was inversely 
related to VO2 peak [18]. In this study, the modification in lean and fat mass were 
assessed with dual-energy x-ray absorptiometry (DEXA), for whole-body analysis, 
and with CT-scan for measurement at the limbs.
2.2 MUSCLE LOSS and CHANGES AFTER SCI
In subjects with SCI, the main feature that can be observed in underlesional muscle 
tissue is the atrophy of muscle fibers, and then a transformation of their fiber type.
As in stroke, a spinal cord lesion leads to a reduction in slow-twitch fibers (type I) and 
an increase of fast-twitch fibers (type IIA and IIX). A pioneering work on this  field was 
published in 1976 by Grimby and coll. [20] who showed that vastus lateralis, soleus 
and gastrocnemius muscles of SCI patients were nearly all composed of type II 
muscle fibers.
This  phenomenon can start 4-6 weeks after the injury [21], but this time may vary 
significantly from patient to patient. Another study found a modification in muscle fiber 
composition of rectus femoris between 7 and 9 months after the lesion, while at 4 
months no significant modification was observed [22]. Soleus and gastrocnemius 
muscles in SCI patients show a similar patern, with a shift towards more rapid fibers 
that becomes evident after 7-8 months after the injury [23]. Castro et al. [24] showed 
that the fiber type shift does not occur within the first 6 months after the lesion.
So, fiber type shift is  slow and progressive, and probably reaches a steady-state 
between 20 and 70 months after the SCI [21]. Then, after this  period, the infralesional 
muscles are almost exclusively composed by rapid fibers  [21,25,26]. These 
observations are not always generalizable; actually it is possible that other factors 
(genetic, spasticity, or other) can modify this  transformation. This hypothesis has 
been confirmed by findings obtained in long-standing SCI patients  who did not show 
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these alterations in muscle fibers composition [27,28]. Along with these modifications, 
a decline in oxidative enzymatic activity of muscle has been observed, and this 
phenomenon probably reflects the shift towards a faster muscle fiber composition 
[29].
All these pathological modifications are preceded by a severe muscle atrophy, that 
develops early after the spinal lesion. 
Muscle atrophy is not unique for SCI, and it has been considered for a long time as 
mainly dependent by the absence of weight-bearing. So, researchers used different 
experimental models as bed rest [30] or microgravity during spaceflights [31] to study 
muscle atrophy after SCI. However, a spinal cord lesion differs from these models 
since muscles are affected not only by unloading, but reduction or absence of 
neuromuscular activity as well. Therefore, in SCI patients, along with a pronounced 
muscle atrophy, a reduced oxidative capacity and various alterations in 
microvasculature can be observed [22,32]. 
Another factor that is involved in SCI is denervation-induced atrophy, that results 
from injury to motoneurons in the spinal cord or to the motor nerves in the ventral 
roots, through which they exit. Muscles that lose innervation through this mechanism 
undergo a rapid wasting. Usually, the percentage of muscles that suffer complete 
denervation is small, but it should be remembered that many peripheral nerves 
receive fibers from different roots, and so partial denervation can affect different 
muscles [33]. This phenomenon is more clinically evident for lesions at the cervical 
and the lumbosacral enlargement (C4 to T1 and L2 to S3, respectively). 
In patients with incomplete SCI, Gorgey et al. [34] found a reduction up to 33% in 
tight cross-sectional area at 6 weeks  only after SCI, with an increase of intramuscular 
fat up to 126%; moreover, intramuscular fat progressively increased until 6 months. 
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In fact, in chronic complete SCI patients  (mean duration of injury 8 years), 
intramuscular and subfascial fat can be increased up to 4 times as compared to 
healthy subjects, and after 8-10 years of denervation adipocytes can constitute up to 
30% of the area in muscle biopsies [35].
In SCI, muscle atrophy magnitude depends from the completeness  or not of the 
lesion as well [36]. In incomplete SCI (ASIA C and D) patients, at a mean time of 13 
months from lesion, a reduction of muscle cross-sectional area of 24% to 31% 
(tibialis anterior and quadriceps femoris, respectively) has  been measured, with a 
small correlation with ambulatory status (considered as the use of wheelchair or not) 
[36]. This reduction is  nearly one half the one that can be seen in complete SCI 
patients [24]. 
2.3 PATHOPHYSIOLOGY of ATROPHY in CNS DISEASES
The pathophysiological mechanisms leading to muscle atrophy in humans are 
complex and not completely understood. To have a better insight about this  topic, the 
readers are suggested to refer to some review that have been published in the last 
years [37-40].
However, the main mechanisms of muscle atrophy after a CNS disease can be 
resumed as it follows:
a. Myostatin dysfunction
b. TNF-α dysfunction
c. Oxidative stress
d. Decreased protein synthesis
e. Increased Proteolysis-Autophagy
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2.3.1. Role of Myostatin
Myostatin is a protein belonging to the TGF-β family, which is a strong negative 
regulator of muscle growth. Some muscle-wasting diseases as HIV-induced cachexia 
[41] or heart failure-related cachexia [42], for example, are characterized by 
increased levels of myostatin. Although myostatin levels seems to be rapidly reduced 
during and after exercise in both healthy subjects [43,44] and in patients with CNS 
injury [45], its role in disuse atrophy is not so clear.
In fact, in a rodent model of disuse atrophy, knockout mice for the myostatin gene 
showed an extent of muscle atrophy that was equal or greater than the one observed 
in wild-type mice in response to unloading [46]. In patients with SCI lasting for more 
than 3 months and showing muscle atrophy, myostatin mRNA levels  were 
significantly reduced, as compared to healthy controls, while the plasmatic levels of 
myostatin did not differ [47]. on the contrary in stroke patients, Ryan et al. found 
higher mRNA levels  in the paretic vastus lateralis muscle compared to controlateral 
healthy side in stroke survivors with hemiplegia from more than 6 months [45]. 
Moreover, the role of myostatin is probably more complex considering the fact that it 
can act only via the interaction with the activin IIB (ActIIB) receptor. This receptor is 
up-regulated during unloading-induced atrophy in rats [48], so the sensitivity of 
muscle to myostatin can be increased in this condition. In light of these 
considerations myostatin seems to play a role in disuse muscle atrophy, which is 
probably less important than in cachexia and age-related sarcopenia.
2.3.2 Role of TNF-α and TNF-superfamily cytokines
TNF-α and other cytokines as IL-1 and IL-6 are involved and increased in cachexia, 
suggesting a possible role in disuse muscle atrophy. TNF-α, binding on TNF receptor, 
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can activate an IKK-dependent pathway that in turns activates NFκB and MURF-1, 
thus leading to an increased proteolysis (see Fig. 1). The activation of this pathway 
has been demonstrated in a rodent model of disuse atrophy [49]. The NFκB 
transcription factor is another protein implicated in disuse muscle atrophy, even if the 
controlling pathway of its action has not been well elucidated in humans [50].
A member of the TNF-superfamily, TNF-related weak inducer of apoptosis (TWEAK), 
has shown to produce, in rodents, a more potent muscle atrophy than TNF-α [51]. 
TWEAK is a strong inducer of the ubiquitin-proteasome pathway and can increase 
the expression of atrogin-1 and MuRF1 in myotubes and inhibit the PI3K/Akt pathway 
[51]. 
It has been demonstrated in humans that TNF-α mRNA expression in paretic vastus 
lateralis of hemiplegic stroke survivors was increased, as  compared to non-paretic 
controlateral side [52]. However, these findings have not been confirmed in a further, 
recent study [53]. So, the exact role of TNF-α in human disuse musce atrophy is still 
not clear.
2.3.3 Role of Oxidative stress
Another area of interest in disuse atrophy is the role of oxidative stress. During 
unloading, there is  an activation of superoxide dismutase, with a decrease in the 
action of other enzymes acting on reactive oxigen species (ROS) [54]. Oxidative 
stress is  a potent inducer of NFκB [55] and FoXO [56] signalling pathways in muscle 
cells, and both act on increasing protein degradation throught the ubiquitin-
proteasome pathway [57]. The causal link between the mitochondrial network and 
denervation-induced muscle atrophy was established in 2010 by an italian research 
group [58], and more recently it has been demonstrated that the increase in 
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mitochondrial ROS production plays an important role in disuse muscle atrophy [59]. 
The oxydative stress  is moreover, a possible target of new therapies for muscle 
atrophy. In fact, Min et colleagues showed in rodents that the administration of a 
mitochondrial-targeted antioxidant not only reduced mitochondrial reactive oxigen 
species, but also reduced myofiber atrophy resulting from unloading [60]. Even if 
oxydative stress  is a relatively new and interesting area of research, this mechanism 
is still not proven in human disuse atrophy.
2.3.4 Role of Decreased protein synthesis: alteration of signals affecting protein 
synthesis (Akt/mTOR pathway)
Akt is a protein kinase that plays a central role in muscle hypertrophy and in protein 
synthesis. It is  a part of the IGF-1 axis, that, after the phosphorilation of the Insulin 
Receptor Substrate, activates phospatidil-Inositol-3-Kinase and produces 
Phosphatidilinositol-(3,4,5)-triphosphate. This  substance phosphorilates Akt and 
consequently activates it. Akt, in turn, activates, through phosphorilation, Tuberous 
Sclerosis  Complex protein 1 and 2 which inhibites  Ras homolog enriched in brain 
(Rheb), which activates mammalian target of rapamycin (mTOR). Activated mTOR 
forms two protein complexes, mTORC1 (binding to Raptor protein) and mTORC2 
(binding to Rictor protein). mTORC1 acts as  a direct activator of protein synthesis, 
activating the S6K1 protein, ,inhibiting the binding proteins  for the eukariotic 
translation initiation factor 4E (4EBP1), and blocking, by phosphorilation, the GSK3β 
protein (which is  a blocker of the eukariotic translation initiation factor 2B) [38,61]. For 
a brief summary of Akt/mTOR pathway see Fig. 1.
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2.3.5 Role of Increased proteolysis
Probably the most relevant role in sustaining disuse atrophy is played by the 
increased proteolysis rather than the reduced protein synthesis. During disuse 
atrophy the myofibrillar component of muscle proteins (mostly actin, myosin, titin, 
vinculin, nebulin) is  early lost. This phenomenon involves three major cellular 
systems:
a) the ATP-dependent ubiquitin-proteasome pathway 
b) the lysosomes 
c) the calcium-dependent calpain system.
a. ATP-dependent ubiquitin-proteasome pathway
The ATP-dependent ubiquitin-proteasome pathway is a proteolytic system that 
utilizes three classes of enzymes at least, named E1, E2 and E3 [62]. 
This  is probably the most important pathway involved in disuse atrophy of the 
muscle. Evidence for its role in disuse muscle atrophy have been shown for several 
years [63], and more recently, it has been clearly shown that in this form of muscle 
atrophy some proteins that act as ubiquitin-ligases  (MuRF1 and MAFbx/Atrogin-1) 
are markedly upregulated [64-67]. At present time, MURF1 and MAFbx are among 
the most promising targets  for designing novel drugs against disuse atrophy [68]. The 
ubiquitin-proteasome pathway is rapidly activated in disuse atrophy, since there is 
evidence, in healthy human volunteers, that the mRNA and the protein MURF1 and 
MAFbx levels  increase after 4 days only of unloading [69]. The ubiquitin-proteasome 
pathway in disuse atrophy seems to be more activated in young adults  compared to 
what observed in elderly adults [69]. 
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b. Lysosome-dependent proteolysis
Lysosome is another component involved in proteolysis. In vitro experiments have 
clearly shown that in disuse atrophy and in unloading there is an increased level of 
mRNA coding for cathepsins, one of the most important enzymes in lysosomes [48]. 
However, their role in disuse atrophy is  not so straightforward, since it has been 
shown that, if an atrophying muscle is  treated with a cathepsin-inhibiting agent, the 
degradation rate of the myofibrillar component of muscle is not affected [70]. For this 
reason, the lysosomal system seems to play a very important role in degrading 
membrane proteins, ione channels and receptors. 
c. Calcium-dependent calpain system
Even if actin and myosin, which are the most represented proteins in skeletal muscle, 
can not be degraded by calpains, this  calcium-dependent system is capable to act on 
scaffolding proteins of muscle as titin, vinculin, C-protein and nebulin [71], and its role 
has been demonstrated in a murine model of disuse atrophy [72]. What makes this 
system important in skeletal muscle atrophy is that, even if the ubiquitin-proteasome 
pathway is probably the most important one, myofibrillar protein degradation is  not 
able to start if the scaffolding and assembly proteins are not degraded.
In muscle atrophy dependent from neurological diseases as stroke an SCI, the exact 
role and timing of action of the aforementioned systems is still not clear.
While in acute phase after CNS lesion it is  highly probable that multiple events take 
place leading to muscle atrophy [73], in chronic phase a new steady state is  probably 
reached, with an inhibition of muscle autophagy mechanisms. In fact, in SCI and 
stroke survivors, two different research groups found that the ubiquitin-proteasome 
pathway activity was comparable to the one observed in age-matched controls 
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[58,74]. Only Ryan and colleagues found an increase in muscle myostatin in the 
paretic side of chronic stroke survivors  [45], that positively responded to active 
exercise.
The only study performed during the first week after SCI, showed an increase in 
gene expression of Atrogin-1, MURF1, UBE3C (an E3 ligase) and PSMD11 (a 
component of 26S proteasome, which is  a part of the proteinase complex responsible 
for cleavage of peptides in the ATP/ubiquitin-dependent process), along with an 
increase of the gene expression for metallothioneins 1A, 1F and 1H and of the 
secretory leucocyte protease inhibitor (SLPI). However, the western blot analysis 
revealed that only PSMD11 protein level was increased following SCI [75]. 
In a study carried on patients with amyotrophic lateral sclerosis, while the mRNA for 
Atrogin-1 and MuRF1 was  increased along with a reduction in Akt activity, the levels 
of protein content of p70s6k and GSK-3β were not changed [76]. This suggests that 
other transcription factors or other signaling pathways  can be involved in the 
pathophysiology of muscle atrophy.
In conclusion at present time not only the exact mechanism of disuse atrophy after a 
CNS lesion is unclear, but also the time at which different systems are over/
underactivated is not completely known.  
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Fig. 1 - Main pathways  involved in muscle metabolism (taken From Carda S, 
Invernizzi M 2013)
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3 BONE and MUSCLE NETWORK
3.1 - BONE-MUSCLE CROSSTALK
The evidence of a biochemical crosstalk between different body tissues has been 
widely demonstrated, however, in last few years, a simple mechanical correlation 
between bone and muscle tissue has been postulated [77]. 
However, some pathological conditions  like sarcopenia, extended bed rest and 
osteoporosis  in absence of gravity have clearly suggested more complex 
pathophysiological mechanisms than just mechanical stimulation [78-80]. Recently, it 
has been observed that skeletal muscle behaves like an endocrine and paracrine 
organ, being able to produce many cytokines, called “myokines” (i.e. Il-6,8,15), after 
different stimuli like contraction [81-83]. These factors are emerging as  key 
modulators of glucose and fat metabolism and of the general responses to physical 
activity [84-86]. 
Similarly, it has been widely demonstrated that bone tissue has some important 
endocrine functions apart from the classic ones like architectural acitivity and mineral 
metabolisms [87]. 
A key role in this endocrine activity is played by osteocytes, dendritic like cells 
derived from osteoblasts that lost their capacity to create new bone tissue. They are 
the main mechano-sensitive cell in the bone, able to up or down-regulate bone 
remodelling in response to mechanichal load [88]. These effects are mediated by 
secreted factors acting on other tissues [89]. However only in the few years it has 
been hypothesized that bone and muscle could be functionally related not only for 
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proximity aspects but also through a biochemical crosstalk sustained by these 
factors.
At present time only few studies, mainly performed in vitro, investigated the possible 
factors related in the biochemical crosstalk between muscle and bone tissue. Among 
these Prostaglandin E2 (PGE2) is one of the most promising, exerting potent 
myogenic differentiation effects on C2C12 myoblasts as evidenced by morphological 
changes, robust modifications in gene expression profile, and very intriguing changes 
in intracellular calcium homeostasis [90].
Thus authors postulated a biunivocal crosstalk between these two tissues, in which 
the factors produced by osteocytes could be targeted to muscle, and muscle-derived 
soluble factors could be targeted to bone [90].
3.2 - PGE2 and Cyclooxygenase
PGE2 is  the most physiologically abundant eicosanoid, which is produced 
predominantly from arachidonic acid by cyclooxygenase (COX) and PGEs enzymes, 
and found at various levels in nearly all cell types. PGE2 acts  on four different 
receptors named prostaglandind E recepor (EP) 1 through 4 yielding an astounding 
array of biological effects. Reported effects include: potent vasodilation, smooth 
muscle relaxation, both anti- and pro-inflammatory activities, bone resorption 
stimulation, synergy with LTB4, replication of AIDS virus  facilitation, sleep/wake cycle 
regulation, thermoregulatory activity in the CNS, LHRH release stimulation from rat 
median eminence, protective effect on gastric mucosa, and renal hemodynamics 
regulation and sodium excretion. This amount of functions makes PGE2 an invaluable 
tool for research in a multitude of areas. PGE2 (Prostaglandin E2) is an inhibitor of 
ERK [91].
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Additionally, EP receptors have been subdivided into four groups, termed EP1, EP2, 
EP3 and EP4. In the early 1990s, cDNA cloning identified a family of eight G-protein 
coupled receptors (GPCRs) that correspond to these pharmacologically-defined 
receptors [92]. 
As a broad generalization, EP1 and EP3 receptors mediate excitatory effects, while 
EP2 and EP4 receptors mediate inhibitory effects. EP1 receptors are believed to be 
coupled via regulatory G proteins to (PLC-independent) influx of extracellular Ca2+; 
phosphatidylinostol hydrolysis ensures as a consequence of this influx [93]. EP3 
receptors are subject to splice variance at the C-terminus [94,95] and, to date, ten 
isoforms have been identified across species, six of these being expressed in man 
[96]. These isoforms differ in their G-protein coupling thereby contributing to the wide 
spectrum of EP3 receptor actions: contraction of smooth muscle, enhancement of 
platelet aggregation, inhibition of autonomic neurotransmitter release, inhibition of 
gastric acid secretion, and inhibition of fat cell lipolysis [97,98]. There is no published 
evidence that splice variance influences ligand affinity. EP2 and EP4 receptors 
preferentially couple through Gs protein to stimulate adenylate cyclase [95]. The 
functional selectivity of natural and synthetic EP4 receptor agonists has  been 
assessed in terms of cAMP production, Gαi1 activation and β-arrestin 2 recruitment 
[99]. Both EP receptor subtypes may be present on smooth muscle cells  with the 
latter usually showing considerably higher sensitivity to PGE2.
PGE2 is one of the major products of arachidonic acid through COX-1/2 pathways. In 
the past decades, it has been related to inflammation, pain and cancer development. 
On the other hand, PGE2 is  important in regulation of physiological functions, such as 
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sodium and chloride transport in the kidney and smooth muscle tone, suggesting for 
itself or its derivatives a useful role in treatment of a number of diseases. Some 
patents associated with the application of PGE2 in diagnosis and therapeutics have 
been summarized in Table 1 [100-108].
To date, one patent only has been filed concerning with the effect of PGs on skeletal 
muscle [100]. Given the extensive usage of PGE2 in disorders in other tissues, there 
is  a great potential for patenting the employment of PGE2 for the functional regulation 
of skeletal muscle and treatment of muscle diseases, such as muscle dystrophy.
Skeletal muscles  are the source of “myokines” with known effects on fat and body 
metabolism [109]. On the other hand, bone cells, and particularly osteocytes are 
known to produce ATP, nitric oxide, prostaglandins (major one being PGE2), 
sclerostin, fibroblast growth factor 23, MCP-3, and many other factors [110-114]. 
Therefore, osteocytes can be viewed as a source and potential reservoir of factors in 
bone with the intrinsic potential of influencing other tissues. Given the intimate 
relationship between bone and muscle during development and life span [115], it is 
reasonable to assume that bone secreted factors might influence muscle behavior 
and function, but this hypothesis has not yet been investigated in a detailed and 
systematic manner.
Muscle mass restoration depends  on myofiber growth, which is facilitated by changes 
in protein metabolism and the reversal of atrophy-induced catabolic pathways [116]. 
In some cases, growth of atrophied myofibers also requires the incorporation of 
additional myonuclei to replace those lost during atrophy [117] and this is associated 
with inflammation [118]. A greater understanding of the regulation of these processes 
is critical for the development of therapies to enhance growth of atrophied muscle.
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Table 1
Selected Patents related with usage of PGE2 in diagnosis and therapeutics
Patent # Title Target Inventor(s)
US 6291528 Prostaglandin E1/F2 in combination with
prostaglandin F2.alpha. for enhancing female
sexual arousal
Female sexual arousal
dysfunction
Nathan Earl Scott
US 6476074 Method and composition for treatment of
erectile dysfunction
Impotence Johan Stjernschantz, Bahram Resul
US 6545045 Prostaglandin E agonists for treatment of
glaucoma
Glaucoma and/or ocular
hypertension
Peter G. Klimko, Najam A. Sharif,
Brenda W. Griffin
US6841573 Use of arachidonic acid as a method of
increasing skeletal muscle mass
Skeletal muscle William Charles Llewellyn
US 6610719 Use of prostaglandin (PGE2) receptor a (EP4)
selective agonists for the treatment of acute
and chronic renal failure
Renal failure Vishwas M. Paralkar, David D.
Thompson
US 8168428 Method to modulate hematopoietic stem cell
growth
Stem cell Leonard I. Zon, Trista E. North,
Wolfram Goessling
US 2010/0267826 A1 Treatment of ischemic episodes and
cerebroprotection through Prostaglandin E2
(PGE2) EP2 and/or EP4 agonists
Ischemia Katrin Andreasson
US 2010/0278875 A1 Prostaglandin E2 (PGE2) as an adjuvant in
monoclonal antibody generation
B cell Jill Giles-Komar, Michael A. Rycyzyn
US 2011/0201684 A1 EP2 Agonist from Non-Prostanoid Structures
Designed as PGE2 Antagonists
Ocular hypertension David F. Woodward, Jenny W. Wang
Recent Pat Biotechnol. Author manuscript; available in PMC 2013 August 03.
Table 1 - Selected Patents related with usage of PGE2 in diagnosis and therapeutics 
- taken from Mo et al. [90]
Enzyme cyclooxygenase COX-2 is  one of two isoforms of COX that catalyzes the 
rate-limiting step in the synthesis of prostaglandins, and are potent regulators of 
inflammation [119]. It has been demonstated that the COX-2 pathway regulates 
myofiber growth in mice following injury that causes extensive degeneration [120]. 
Growth of regenerated myofibers was attenuated by the COX-2-selective inhibitor 
SC-236 as well as in COX-2 -/- mice [120]. This effect was  associated with the 
presence of fewer myoblasts within regenerating muscles, implicating adverse effects 
on myoblasts as a potential mechanism behind attenuated myofiber growth. 
Regenerating muscles from SC-236-treated mice and COX-2 -/- mice also exhibited 
decreased inflammation.
26
Whether COX-2 regulates  myofiber growth under diverse physiological 
circumstances or specifically during muscle regeneration is not clear. Muscle 
regeneration involves the replacement of necrotic myofibers  via de novo myofiber 
formation and involves a robust inflammatory response [121]. Because myonuclei 
within existing myofibers are postmitotic, myofiber formation and subsequent growth 
depends on the activation, proliferation, differentiation, and fusion of muscle 
precursor cells (MPC). MPC, called also satellite cells, lie mainly between the basal 
lamina and sarcolemma and are quiescent cells  that become activated to reenter the 
cell cycle and proliferate by various growth factors and cytokines produced during 
muscle growth [122]. In contrast to regeneration, restoration of muscle mass after 
atrophy involves the growth of existing myofibers. In mice, reloading of muscles that 
have been atrophied by unweighting typically causes minimal myofiber degeneration 
despite the occurrence of some myofiber membrane damage and inflammation [123]. 
Growth of atrophied myofibers not only involves anabolic processes to facilitate 
myofiber growth but also the reversal of catabolic processes that were induced 
during the atrophy period [124]. In addition to myonuclear loss, atrophy is  also 
associated with the loss of MPC, and the remaining MPC exhibit impaired 
proliferation and differentiation [125]. Thus the physiological state of atrophied 
muscle before reloading is distinct from that of degenerating muscle and may 
necessitate alternative mechanisms to facilitate regrowth.
It has been demonstrated that treatment with the COX-2 inhibitor SC-236 attenuates 
myofiber growth in both the soleus and plantaris muscles  after atrophy. Moreover, 
there is  evidence for the involvement of COX-2 in myonuclear addition and 
inflammation during growth in the soleus but not the plantaris, suggesting that 
multiple mechanisms underlie COX-2 function in muscle growth. Finally, in vitro 
27
evidence suggests that regulation of myonuclear addition by the COX-2 pathway may 
be attributable to direct regulation of muscle cells.
3.3 SCLEROSTIN - UNLOADING MEDIATOR IN BONE
Sclerostin is a Wnt signaling antagonists. The Wnt signaling pathway has recently 
been identified as central to the development of disuse osteoporosis [126–130]. Wnt 
binds to a co-receptor complex involving Frizzled receptor and low-density lipoprotein 
receptor-related protein (LRP)-5 or LRP- 6, both present on osteoblasts. This binding 
stabilizes cytoplasmic à-catenin and causes  it to translocate to the nucleus. 
Translocation of alpha-catenin, in turn, activates the transcription of genes that 
promote osteoblast proliferation, differen- tiation, and function, ultimately resulting in 
new bone formation. Sclerostin inhibits the Wnt pathway by prevent- ing the 
formation of the Wnt-Frizzled-LRP5 complex by competitive binding to LRP5 [131, 
132]. Mechanical unloading causes  upregulation of sclerostin [133] and therefore 
inhibited bone formation via suppressed osteoblast activity and survival. Animal 
models  clearly demonstrate elevated sclerostin levels in response to mechanical 
unloading that is  reversed with reloading [129] Based on these reports, sclerostin 
levels  are expected to be initially elevated with the withdrawal of mechanical loading 
after SCI.
3.4 MYOSTATIN - REGULATOR OF MUSCLE CELLS PROLIFERATION AND 
DIFFERENTIATION
Satellite cells are undifferentiated cells  that in physiological conditions lie in a 
quiescent state in the muscular tissue. Their differentiation is regulated by a family of 
transcriptional factors called myogenic regulatory factors (MRFs) such as MyoD, 
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Myf5, myogenin and MRF4. They initiate and coordinate the differentiation of satellite 
cells to mature muscle cells. Myostatin is  a member of TGF superfamily which is 
mainly expressed in satellite cells. This molecule inhibits  MRFs and overall muscle 
differentiation and growth both in vivo and in vitro [134]. Since muscular hypertrophy 
is  mainly sustained by the activation of local satellite cell after a muscular contraction 
of certain intensity and duration, [135], the inhibition of the myostatin pathway could 
be a key target to facilitate muscle growth after physical exercise. 
In line with this hypothesis, an animal study of chronic heart failure suggested that 
cardiac tissue under stress conditions is able to synthetize myostatin, which acts at 
both peripheral level inducing muscle wasting, and at central level inducing apoptosis 
and fibrosis of cardiomyocytes. It has  been hypothesized that this pathophysiological 
pathway could actually reduce the circulatory load, thus reducing the energy 
expenditure of the heart in stress conditions [135]. Interestingly, a physical exercise 
protocol restored myostatin to physiological levels in both myocardium and skeletal 
muscles over a period of 4 weeks: this reduction could be due to the direct and 
indirect effects of exercise on the expression of proinflammatory cytokines [136].
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STUDY DESIGN
Phase 1. Development of a new method to collect bioptic samples from skeletal 
muscle and histological characterization of SCI subjects skeletal muscle
 
Skeletal muscle biopsy is a minor surgical procedure that has been conducted over 
several decades for the diagnosis of different neuromuscular pathological conditions.  
This technique has recently gained popularity also in the research field of age-related 
muscular modifications and sarcopenia [137] evolving from surgical “open approach” 
to less invasive techniques, in order to be easier to perform and to be more tolerable 
for the patient [138]. 
Skeletal muscle contains several fiber types deeply differing in their chemical 
composition and consequently in their twitch properties. It is generally accepted that 
muscle fiber types can be divided into two main types: slow twitch (type I) and fast 
twitch (type IIa,b,c) muscle fibers. Slow twitch fibers fire more slowly than fast twitch 
fibers and can sustain contraction for long periods of time before they fatigue; on the 
other hand fast twitch fibers generate faster strenght and speed but they fatigue more 
quickly. These distinctions seem to influence how muscles respond to training and 
physical activity, and each fiber type is unique in its ability to contract in a certain way 
[139-141]. On average, human muscles contain an equal percentage of slow and fast 
twitch fibers, however it has been reported a switch in this ratio in some pathological 
conditions like chronic neurological diseases and in particular spinal cord injury (SCI) 
[20,142]. Thus, fiber type discrimination is essential to distinguish between normal 
and pathological skeletal muscle tissue.
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Prostaglandins (PG) are a family of active compounds produced by the ubiquitous 
cyclooxygenase (COX) enzymes (COX I and II) and elicit an array of tissue-specific 
functions [143-145]. There are different types of PG, with prostaglandin E2 (PGE2) 
playing a pivotal role in both bone and muscle tissue biology [90,146]. In bone tissue 
PGE2 is responsible of bone resorption, while in skeletal muscle, PGE2 produced by 
both isoforms of COX [146,147], regulate protein synthesis and degradation after 
exercise [148-150], along with being involved in muscle tissue injury recovery 
[151,152]. PGE2 receptors are classified into four subtypes, Ep1, Ep2, Ep3, and Ep4, 
all of which interact with different G-proteins and their subsequent signaling pathways 
[153,154].
At present time few studies focused on the application of mini-invasive biopsy 
techniques on skeletal muscle tissue in both normal and pathological conditions. 
Moreover the possible role of COX and PG in determining muscular modifications 
after SCI has not been investigated yet. 
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Phase 2. A possible link between muscle and bone in spinal cord injuried patients: 
evaluation of serum myostatin and sclerostin levels
Osteoporosis  after Spinal Cord Injury (SCI) affects  mainly underlesional bones like 
distal femur and proximal tibia with consequent increased fracture rate at these sites 
[155-157]. However, despite the severity and the high complication and disability 
rate, at present time evidences about osteoporosis management after SCI are scarce 
[158-163].
Both animal and humans models show that unloading is the main determinant of this 
condition, probably through the Wnt signaling pathway, that has been recently 
identified as  one of the key regulators of mechanical load responses in bone [158, 
164-166]. Sclerostin, produced by osteocytes, is a powerful selective inhibitor of Wnt 
signaling, inducing a reduction of osteoblast activity and proliferation that ultimately 
result in the loss of bone mass [167]. Recently, Morse et al. found a strong 
correlation between Bone Mineral Density (BMD) and serum sclerostin in SCI 
patients, suggesting that sclerostin could be a circulating biomarker that can be used 
as a complement or as a substitute of Dual X-Ray Absorptiometry (DXA) to assess 
osteoporosis and to monitor its treatment in chronic SCI patients [167,168]. 
Pathological muscular modifications in SCI patients  are as severe as those at bone 
level, with an heavy impact on disability and comorbidities [167]. However, compared 
to bone and osteoporosis, research conducted at muscle tissue level in SCI patients 
is  far from diagnosis, prevention and treatment and the pathophysiological 
mechanisms underlying these modifications remain still unclear [142]. Recently, the 
evidence of a biochemical crosstalk between muscle and bone tissue has been 
postulated, overtaking the previous hypothesis of a simple mechanical correlation 
between these two tissues [77, 170]. At present time only few studies, and mainly 
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conducted in vitro, investigated the possible factors  involved in the biochemical 
crosstalk between muscle and bone tissue. These studies, conducted in vitro on 
myoblast lineage cells (C2C12), gave interesting results  about the possible existence 
of a biunivocal crosstalk between bone and muscle, in which the factors produced by 
osteocytes could target muscle, and muscle-derived soluble factors could target bone 
[90]. Whereas on the one hand osteocytes and sclerostin are responsible of the 
crosstalk between bone and muscle, on the other hand, satellite cells at muscular 
level could play a role in the opposite way. Myostatin is a powerful inhibitor of overall 
muscle differentiation and growth both in vivo and in vitro [134]. Since the inhibition of 
myostatin pathway is a key target to facilitate muscle growth, myostatin could be 
used as  a possible biomarker to monitor the evolution of muscular modifications in 
SCI patients and, be a potential therapeutical target. However, at present time, serum 
myostatin levels in SCI patients have not been determined yet.
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AIM OF THE STUDY
As previously evidenced, considering the few reports present in literature about mini-
invasive biopsies at skeletal muscle level in both normal and pathological conditions, 
the aim of our study was to describe a mini invasive ultrasound-guided skeletal 
muscular biopsy technique in complete SCI patients and healthy controls with a tri-
axial end-cut needle (Biopince© - Angiotech). Moreover this study focused on 
morphological (fiber type discrimination), molecular (COX and EPs gene expression) 
and practical procedure related aspects (feasibility, complication rate and accuracy).
In the second phase of the study the aim was to assess in a population of chronic 
SCI patients the serum myostatin concentration, being a possible candidate 
biomarker of muscular modifications in these patients. Secondarily, assuming the 
previously described crosstalk between bone and muscle tissue and the key role of 
osteocytes, a possible correlation between serum myostatin levels, serum sclerostin 
levels and BMD in these patients has been investigated.
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MATERIALS and METHODS
Subjects
28 chronic SCI patients were consecutively enrolled from the Physical and 
Rehabilitation Unit of the AOU “Maggiore della Carità” in Novara (Italy).
Demographical data are resumed in Table 2. Inclusion criteria were the following: 1) 
spinal cord injury; 2) a grade from A to C on the American Spinal Injury Association 
(AIS) Impairment Scale [171,172]; 3) level of neurological spine injury ranging from 
C5 to T12; 4) age > 18; 5) time from lesion > 2 years (24 months). The exclusion 
criteria were: diabetes; oral anticoagulation; other chronic neurological pathologies, 
use of drugs acting on bone metabolism (bisphosphonates, corticosteroids, lithium, 
anticonvulsivants, parathyroid hormone analogues, estrogens) and muscle (statins). 
Moreover 15 healthy controls were enrolled and the inclusion criteria were the 
following: 1) absence of SCI and/or any other neurological pathology; 2) absence of 
muscolo-skeletal pathologies; 3) absence of any kind of gait impariment; 3) age > 18; 
4) abstention from intense physical activity at least in the 24h before serum sample 
collection. The exclusion criteria were the same as the SCI group. 
Among the SCI group, 6 patients were consecutively enrolled to perform a mini-
invasive skeletal muscle biopsy. Inclusion criteria were the following: spinal cord 
injury graded A or B on the AIS scale. Exclusion criteria were: diabetes; oral 
anticoagulation; osteosynthesis of the femur; and history of hepatitis  B, C, or D or 
human immunodeficiency virus (HIV) infection. Muscle specimens of 3 healthy 
controls were obtained during knee surgery for cruciate ligament reconstruction in 
operatory room under sedation. The inclusion criteria for controls  were the following: 
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age > 18. The exclusion criteria were the same as SCI group. Demographic data of 
these sub-groups are resumed in Table 4.
 
Written informed consent was obtained from each patient before the biopsy after a 
full explanation of the procedure which was conducted according to the Declaration 
of Helsinki guidelines. 
Study procedure
All patients at baseline underwent a physical examination by a trained physician and 
motor impairment was determined using AIS impairment scale [171,172]. According 
to the AIS score, patients were divided in two groups: complete motor underlesional 
paraplegic (AIS A,B) and incomplete motor underlesional paraplegic (AIS C).
For SCI patients, the level of disability was measured with the Italian version of the 
SCIMIII scale [173]. After enrollment all patients underwent blood sample and BMD 
measurement in the same morning.
Among the SCI complete group, 6 patients  performed a skeletal muscle biopsy on 
separate days from blood sample collection and BMD measurement. A diagram of 
the study procedure is represented in Figure 2.
Muscle Biopsies
Skeletal muscle samples were obtained using a percutaneous tri-axial end cut needle 
(Biopince© - Angiotech) of 18-gauge. Biopsies were collected from vastus lateralis 
muscle at two-third of the distance from trochanter as previously described by Leger 
et al. [47,174]. Correct needle positioning in the target muscle was confirmed by 
ultrasound (US) Hitachi - EUB-5500 Digital Ultrasound Scanner©), performed by a 
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physician with specific experience in muscular sonography with a linear transducer 
(AL53L - scanning frequence 10 MHz). All biopsies were performed under local 
anesthesia (lidocaine 1% in 5ml). A single incision was made in the skin, and two 
different muscle samples were consecutively taken for each patient. 
The stroke length of the biopsy was adjusted according to the muscle size 
considering the presence of blood vessels  and other vulnerable structures proximity; 
33 mm stroke length was chosen whenever possible. All specimen were immediately 
frozen in liquid nitrogen until use. 
Data about procedure related complications, easiness  of needle US imaging and any 
other technical issue have been recorded by the operator. 
ATPase staining
Frozen sections of 10 µm thick were cut at -20°C and stored at -20°C until staining 
procedure. Fiber types were determined by the differential staining resulting from 
incubation at pH 9.6. This staining allows to distinguish type I fiber from type II. 
Samples were incubated with 0.5 mg/mL ATP dissolved in 0.1M glycine/ 0.1M NaCl 
buffer with 0.75M CaCl2, for 11 minutes  at 37 °C. Samples were then rinsed well in 
distilled water and incubated for 5 minutes at room temperature with 2% CoCl2. 
Samples were extensively washed in both distilled and tap water. Specimens were 
then incubated for 30s in 2% ammonium sulphide solution, rinsed well in tap water 
and observed with an optical microscope (Leica DMIL, Leica Microsystems Wetzlar 
GmbH, Wetzlar, Germany).
37
Real-time reverse transcription-polymerase chain reaction (real time RT-PCR)
Total RNA was isolated from the tissue specimen using the Ribozol RNA extraction 
reagent (Amresco). The mRNA was converted into complementary DNA (cDNA) 
using the high capacity cDNA reverse transcription kit (Applied Biosystems). The 
cDNA mixtures were subjected to real-time PCR using SYBR® Green I dye. The 
reactions were performed using  primer sequences (sense and anti-sense), as shown 
in Table 5. All real-time PCR reactions were performed in triplicate using a Biorad 
CFX96 instrument; the gene expression levels  were normalized using GAPDH as 
housekeeping gene and gene expression was calculated as 2^-ΔCt, where ΔCt= Ct 
gene - Ct housekeeping [175].
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Biochemical markers and BMD 
Blood samples were performed at the same hour in the morning in fasting conditions. 
The samples were centrifuged for 15 min at 3000 rpm at 4 °C and stored at -80 °C 
until final analysis. 
Serum calcium, phosphate, and creatinine were measured with the Technicon 
Autoanalyzer SMA-12/60 (Technicon Instruments Corp., Torrytown, NY, USA). 
Plasma ionized calcium was measured by StatProfile M Nova (Milan, Italy); serum 
immuno- reactive 1–84 PTH was measured using a Nichols kit (Nichols Institute, San 
Juan Capistrano, CA, USA). 25 hydroxy Vitamin D (25(OH)D) was assessed with the 
IDS ϒ-B 25-hydroxy Vitamin D kit (Immuno- diagnostic Systems Ltd, Boldon, UK; 
intra-assay coefficient of variation (CV) 6.9%, interassay CV 9%, normal range 75–
300 nmol/l). The other biochemical evaluations were performed by the Biochemical 
Analysis Lab of our Hospital.
Myostatin was measured with Elisa kit (MyBioSource, MBS703668), normal range 
0.625-20 ng/ml; minimum detectable dose less than 0.312 ng/ml. Serum sclerostin 
was measured with SOST Elisa Kit Biomedica Gruppe (Vienna, Austria), with a 
standard range of 0-240 pmol/L, a detection limit of 2.6 pmol/l and a unit conversion 
of 1 pg/ml = 0.044 pmol/L.
BMD of patients and healthy controls was measured with calcaneus ultrasonography 
(Achilles Express© 2001 GE Medical System, Lunar Corporation – Madison, 
Wisconsin, USA), and data about t-score and stiffness were obtained.
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Statistical Analysis
Statistical analyses were performed using the GraphPad 4 package, version 4.0 
(GraphPad Software, Inc., San Diego, CA, USA). Due to the low numerosity of the 
sample we assumed a non-gaussian distribution of the variables taken in 
consideration. After enrollment patients  were divided in two sub-group depending on 
the AIS score: complete and incomplete. Differences between single variables in 
different groups were evaluated with the Mann–Whitney U test. Between-group 
comparisons for 25(OH)D insufficiency prevalence were done using the Fisher’s 
exact test. A type I error level of 0.05 was chosen. Relationships  between serum 
myostatin values and the other variables taken in exam were analyzed with linear 
regression using Pearson’s correlation coefficients. Regression lines were compared 
using confidence intervals. A p value lower than 0.05 was considered statistically 
significant.
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Figure 2 - Flow chart of the study
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RESULTS
Biochemical and BMD evaluation
Demographic characteristics of SCI and control group are resumed in Table 2. SCI 
group showed statistically significant differences  regarding smoke, age and history of 
previous fractures at any site compared to healthy controls while all the other 
demographical variables showed no statistical difference.
Serum myostatin levels  were statistically higher in SCI group compared to healthy 
controls (Fig. 3). Similar results were found comparing the complete SCI sub-group 
and the incomplete SCI sub-group to healthy controls (Fig. 3). 
Serum sclerostin was significantly higher in SCI patients compared to healthy 
controls (Fig. 3). 
Regarding other biochemical variables, PTH and PCR serum values showed 
statistically significant differences between the two groups (Table 3). However the 
mean values in both groups were in the normality range. 25(OH)D serum levels  were 
significantly higher in healthy controls compared to SCI group. However the mean 
value in the control group was far from normality level and only 20% of healthy 
controls showed values of 25(OH)D higher than 30 ng/ml. On the contrary 50% of 
SCI patients showed 25(OH)D values < 10ng/ml.
Regarding BMD, stifness and mean T-score values in SCI patients were significantly 
lower than healthy controls in both total SCI group and each subgroup (complete/
incomplete). Interestingly there was also a statistically significant difference between 
the complete and incomplete subgroup regarding these two variables (Fig. 4). 
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Serum myostatin concentrations in the complete SCI subgroups correlated only with 
serum sclerostin levels (r2 = 0.42; p=0.0012) (Fig. 5) and with none of the other 
variables taken in consideration (Fig. 6).
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Table 2 - Subjects characteristics at enrollment. 
SCI
n = 28
CT
n = 15
Age (years) 40.5 ± 7.07 28.37 ± 4.07
Sex % (F/M) 17.86/82.14 (5/23) 66.67/33.33 (10/5)
Body Mass Index (BMI) 24.68  ± 3.44 22.76 ± 2.09
Smoke (Y/N) 35.71/64.29 (10/18) 0/100 (0/15)
Injury Severity - ASIA score A 18
B   4
C   6
--
Complete/incomplete 78.57/21.43 (22/6) --
Wheelchair use 78.57 (22) --
Etiology
traumatic 75.00 (21) --
non-traumatic 25.00 (7) --
Duration of SCI (months) 90.82 ± 53.11 --
Lesion Level Paraplegia 85.71 
(24)
D1-D12 75.00 (18)
D12-L5 25.00 (6)
Tetraplegia 14.29 (4)
--
I-SCIMIII score 72.78 ± 10.32 --
Fractures (any site) 11 0
SCI: spinal cord injury group; CT: healthy control group; I-SCIMIII: 3rd italian version of the spinal  cord 
independence measure; AIS: American Spinal Injury Association Impairment Scale. Data are 
presented as mean ± standard deviation (SD) or percentage. * p < 0.05
44
Table 3 -  Biochemical and BMD variables between groups
SCI Tot
n = 28
SCI complete
n = 22
SCI incomplete
n = 6
CT
n = 15
25(OH)D (ng/ml) 12.31 ± 6.62 12.61 ± 7.01 11.2 ± 5.31 20.49 ± 7.10 #** ✝✝
Normal (>30 ng/mL)
Low (<30 ng/mL)
Very Low (<10 ng/mL)
0
50.00 (14)
50.00 (14)
0
50.00 (11)
50.00 (11)
0
50.00 (3) §§ ##
50.00 (3) §§ ## 
20.00 (3) + - /
80.00 (12) + - /
0 + - /
Phosphate (mg/dl) 3.02 ± 0.39 3.09 ± 0.39 2.77 ± 0.31 3.06  ± 0.52
Serum creatinine (mg/
dl)
0,98 ± 0.21 1,01 ± 0.22 0,87 ± 0.13 0,93 ± 0.18
eGFR (ml/min/1.73m2) 86 ± 7.8 84 ± 8.1 87 ± 6.9 81 ± 5.4
CTX (pg/ml) 461.70 ± 215.50 479.40 ± 215.82 396.95 ± 220.63 399.20 ± 223.90
PTH (pg/mL) 43.94 ± 13.83 43.41 ± 13.94 45.82 ± 14.57 29.69 ± 6.88
IGF-I (ng/mL) 177.60 ± 47.66 181.21 ± 49.71 164.23 ± 40.21 241.10 ± 92.75
CRP (mg/dL) 0.765 ± 0.44 0.79 ± 0.69 0.67 ± 0.59 0.05 ± 0.04 #** ✝✝
iCa (mg/dl) 4.88 ± 0.24 4.87 ± 0.26 4.91 ± 0.18 4.98 ± 0.18
BALP (mcg/L) 12.59 ± 4.01 12.63 ± 4.32 12.47 ± 2.92 11.63 ± 6.02
Stiffness 36.75 ± 20.00 28.55 ± 12.08 66.83 ± 13.01 § 117.80 ± 18.96 #** 
✝✝
T-score - 4.8 ± 1.6 -5.4 ± 0.9 -2.9 ± 1.1 1.4 ± 1.3
SCI: Spinal  Cord Injury; CT: controls; 25(OH)D: 25 hydroxy vitamin D; eGFR:  estimated glomerular 
filtration rate; PTH: parathyroid hormone; CTX: Serum beta crosslaps; IGF-I: Insulin Growth Factor I; 
CRP: C reactive protein; iCa: ionized Calcium; BALP: Bone Alkaline Phosphatase. Data are presented 
as mean ± standard deviation (SD).
* p < 0.05 Mann Whitney U test SCI Tot vs. SCI complete
✝ p < 0.05 Mann Whitney U test SCI Tot vs. SCI incomplete
# p < 0.05 Mann Whitney U test SCI Tot vs. CT
§ p < 0.05 Mann Whitney U test  SCI complete vs. SCI incomplete
** p < 0.05 Mann Whitney U test  SCI complete vs. CT
✝✝ p < 0.05 Mann Whitney U test  SCI incomplete vs. CT
§§ p < 0.05 Fisher’s exact test SCI Tot vs. SCI incomplete
## p < 0.05 Fisher’s exact test SCI complete vs. SCI incomplete
+ p < 0.05 Fisher’s exact test SCI Tot vs. CT
- p < 0.05 Fisher’s exact test SCI complete vs. CT
/ p < 0.05 Fisher’s exact test SCI incomplete vs. CT
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Figure 3 - Differences between serum sclerostin and Myostatin in all groups. data 
are presented as mean ± standard deviation (SD).* p < 0.05 SCI Tot vs. CT; ** p < 
0.05 SCI complete vs. CT; *** p < 0.05 SCI incomplete vs. CT; # p < 0.05 SCI 
complete vs. SCI incomplete. 
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Figure 4 - Stiffness values in SCI sub-groups and CT. * p < 0.05 SCI Tot vs. CT; 
** p < 0.05 SCI complete vs. CT; *** p < 0.05 SCI incomplete vs. CT.
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Figure 5 - Correlation between serum Myostatin and serum Sclerostin levels. r2 = 
0.42; p=0.0012
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Figure 6 - Correlations between serum myostatin and other study variables.
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Muscle Biopsies
A total of 18 specimens were collected (12 from SCI and 6 from healthy controls). 
Sub-group demographical characteristics are resumed in Table 4. 
All the procedures were performed easily without failures and in all cases the 
specimen was easily removed. Visibility of the needle was  good at ultrasound and 
required in 5 cases only a correction of the angle of the needle to visualize it; 
however in no case had a biopsy to be abandoned because of insufficient visibility of 
the needle. There were no cases of inadequate/insufficient material collection, 
however SCI specimen were macroscopically thinner and brittler compared to those 
of healthy subjects. 
Complications were observed in 40% of the procedures. They were all self-limiting 
small hemorrages requiring no treatment. 
ATPase stained specimen are represented in Fig. 7. Real Time RT-PCR results  are 
shown in Fig. 8.
Preliminary molecular results  about COX-1,2 and EP1,2,3,4 expression showed a 
significantly lower expression of COX-1 in SCI patients  compared to healthy controls. 
A difference was present also regarding EP2 expression, even if not significant (Fig. 
8).
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Table 4 - Demographical data of SCI patients (SCI) and healthy controls (CT) 
underwent muscle biopsy.
SCI
n = 6
CT
n = 3
Age (years) 38.6 ± 7.29 34.69 ± 6.22
Sex % (F/M) 20/80% (1/5) 0/100% (0/3)
Body Mass Index (BMI) 24.68  ± 3.44 22.76 ± 2.09
Smoke (Y/N) 35.71/64.29 (10/18) 0/100 (0/15)
Injury Severity - ASIA score A  4
B  2
--
Wheelchair use 100% (6) --
Etiology --
traumatic 100% (6) --
Duration of SCI (months) 72.56 ± 35.11 --
Lesion Level Paraplegia 100% (6)
D1-D12 75.00 (5)
D12-L5 25.00 (1)
--
I-SCIMIII score 65.48 ± 8.44 --
Fractures (any site) 3 0
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Table 5 - Primers for real time RT-PCR analysis by using the SYBR® Green dye.
Targets Primer sequences (sense and anti-sense)
COX-1 5′-ACCTTGAAGGAGTCAGGCATGAG-3′
5′-TGTTCGGTGTCCAGTTCCAATA-3′
COX-2 5′-CTGGGTTTCCGATTTTCTCA-3′
5′-CAAGCCCATGTGAATGACTG-3′
Ep1 5′-TCTACCTCCCTGCAGCGGCCACTG-3′
5′-GAAGTGGCTGAGGCCGCTGTGCCGGAG-3′
Ep2 5′-TGAAGTTGCAGGCGAGCA-3′
5′-GACCGCTTACCTGCAGCTGTAC-3′
Ep3 5′-GCAGTGCTCAACTGATGTCT-3′
5′-GGACTAGCTCTTCGCATAACT-3′
Ep4 5′-TTCCGCTCGTGGTGCGAGTGTTC-3′
5′-GAGGTGGTGTCTGCTTGGGTCAG-3′
GAPDH 5′-GAGTCAACGGATTTGGTCGT-3′
5′-GACAAGCTTCCCGTTCTCAG-3′
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Figure 7 - Atpase staining of an healthy control (A) and a SCI patient (B). Type I fiber 
stain light and Type II fiber stain dark. Magnification 10x. 
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Figure 8 - RT-PCR of COX-1 in SCI and CT. * p < 0.05 SCI vs. CT
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DISCUSSION
In this study we have shown a statistically significant difference in serum myostatin 
concentration in SCI patients compared to healthy controls; thus, SCI patients, 
considering both complete and incomplete subgroups, showed higher serum values 
of myostatin compared to healthy controls. To our knowledge this is  the first study 
investigating serum myostatin levels in SCI patients. 
Similarly we have confirmed the previously obtained result of a significative increase 
in serum sclerostin levels  in SCI patients compared to non-SCI subjects [167,168]. 
Moreover the differences at bone tissue level between SCI patients and healthy 
controls have been confirmed also by a statistically significant reduction in BMD 
measured at calcaneus level between these two groups. However, while a significant 
correlation between serum myostatin and serum sclerostin was found (r2 = 0.42), 
serum myostatin didn’t correlate with any other variable taken in consideration in this 
study .
Regarding mini-invasive muscular biopsies, this study has highlighted the feasibility 
and accuracy of the tri-axial end-cut needle (Biopince© - Angiotech) biopsy in 
discriminating type I and II muscle fibers in complete SCI patients and healthy 
controls. Moreover the complication rate was also evaluated, showing only self-
limiting hemorrages requiring no additional treatment. Lastly preliminary results 
obtained from real time RT-PCR showed a significative difference in the expression 
of COX-1 gene in SCI patients compared to healthy controls. To our knowledge, 
although preliminary, these are the first data about COX expression in SCI patients. 
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It is noteworthy that the described method to collect skeletal muscle specimen is 
absolutely new and represents a great improvement in term of accuracy of tissue 
collection and of acceptability by the patients.
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Muscle Biopsies
Skeletal muscle biopsy  is often essential in clinical setting to confirm a previous 
diagnosis emerged from imaging or circulating biomarkers. Thus, this approach 
should be a compromise between expected definitive diagnosis and the 
complications and discomfort for the patient. For this reason image-guided 
percutaneous biopsy performed with a fine needle represent an interesting tool to 
solve this issue. A recent paper investigated the feasibility, dignostic accuracy and 
complication rate of biopsies performed in different soft tissues with a tri-axial end cut 
needle (Biopince© - Angiotech). Authors showed that the 18-gauge biopsy needle 
was easy to handle allowing both ultrasound- and CT-guided percutaneous biopsies 
of various organs.The accuracy of biopsies was high, without crush artifacts and with 
low complication rate. However, even if this study was performed on a sample of 100 
cases, only one biopsy has been performed on skeletal muscle [176]. Previous 
studies, available in literature, in which ultra thin (21-25g) needles have been used, 
were limited to citologic diagnosis in malignancies and are not applicable in benign 
lesions or in conditions where larger samples for histological evaluations are needed 
[177]. Thus, in these circumstances, Authors suggest more invasive and technical 
demanding approaches, like core biopsies, in order to obtain a larger specimen for 
histological evaluation. However, the quality  of the specimen does not only  depend 
on the tissue amount but also on the possible presence of crush artifacts and 
pathological modifications of the tissue itself [178]. A good example of pathological 
modifications that could be observed in muscle specimen is represented by SCI, 
where it has been previously described a fiber atrophy, myosteatosis and a shift from 
type I to type II fiber prevalence. This last pathological feature, called “fiber shift” has 
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also been previously described in other chronic neurological conditions like stroke 
[142].
The results obtained in SCI specimen were consistent with previously described 
macroscopic pathological modifications, being thinner and more fragile compared to 
those of healthy controls. For a long time, fiber type determination in muscle 
specimens has been based on the classical myosin ATPase staining method 
developed by  Padykula and Herman in 1955 [179,180]. This method underwent 
several modifications, including the use of glycine buffer instead of sodium barbital 
buffer [181] to incubate tissue specimens. This improvement maintains a constant 
pH, eventually  providing a better histochemical result. Regarding fiber type 
identification, after alkaline ATPase staining, the results obtained in SCI patients were 
consistent with those previously described in literature [20] and the expected shift 
from type I to type II fibers has been observed. 
PGE2 is one of the most promising actor of the bone-muscle biochemical crosstalk, 
exerting potent myogenic differentiation effects on C2C12 myoblasts as evidenced by 
morphological changes, robust modifications in gene expression profile, and very 
intriguing changes in intracellular calcium homeostasis [90]. COX-1 is traditionally 
viewed as a constitutively expressed protein that primarily has homeostatic functions, 
while COX-2 is induced by an array of stimuli, including tissue injury and it is 
hypotesized the existence of some overlap in the function of these enzymes 
[144-152]. Our data, although preliminary, about a significative decrease of COX-1 
expression in SCI patients compared to healthy control, suggest that PG pathway is 
probably involved in determining muscular modifications after SCI. However this 
hypothesis should be taken cautiosly and needs to be deeply investigated.
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Circulating Biomarkers
As we will discuss further on, circulating biomarkers can be a useful surrogate 
measure for both diagnostic and therapeutic monitoring purposes, considering their 
easiness, the low cost and non-invasivity [182]. This is the case of BMD measured 
with DXA technique, which is the gold standard for osteoporosis, but under a 
condition such as SCI, some important technical and accuracy issues are to be found 
[158,161]. 
Myostatin and muscular modifications
In subjects with SCI, the main feature that can be observed in underlesional muscle 
tissue is  the atrophy of muscle fibers, and then a transformation of their fiber type, 
like in stroke, leading to a a reduction in slow-twitch fibers (type I) and an increase in 
fast-twitch fibers (type IIA and IIX) [169]. These modifications, and particularly the 
severe muscle atrophy in chronic complete SCI is a major contributor to comorbidity 
risk factors  such as diabetes, obesity, lipid disorders, and cardiovascular disease 
[20].
Satellite cells are undifferentiated cells  that in physiological conditions lie in a 
quiescent state in the muscular tissue. Their differentiation is regulated by a family of 
transcriptional factors called myogenic regulatory factors (MRFs) such as MyoD, 
Myf5, myogenin and MRF4. These factors  initiate and coordinate the differentiation of 
satellite cells to mature muscle cells. Muscular hypertrophy is mainly sustained by 
the activation of local satellite cell after a muscular contraction of certain intensity and 
duration [135]. Myostatin is  a member of TGF superfamily which is mainly expressed 
in satellite cells. This molecule is a powerful inhibitor of MRFs and overall muscle 
differentiation and growth both in vivo and in vitro [134]. Findings reported in this 
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work suggest that in SCI patients, independently from being complete or incomplete 
and para/tetraplegic, myostatin serum levels are significantly higher than healthy 
controls, explaining, maybe in part, the severe pathological muscular modifications 
observed in these patients. 
Being SCI the extreme pathological unloading condition in humans, these results are 
intriguing, because myostatin, produced selectively by satellite cells in the muscular 
microvenvironment, is  an attractive candidate biomarker to monitor the muscular 
modifications in this patients. Another opportunity could be the use of satellite cells as 
a possible pharmacological target to prevent muscular alterations  and not only in SCI 
patients but also in other unloading pathological conditions (like prolonged bedridden, 
absence of gravity, etc..). Thus, at present time, selective monoclonal antibodies 
against myostatin are under study in humans and could be in the immediate future an 
intriguing therapeutical option to prevent muscular modifications in SCI and other 
unloading-induced pathological conditions. 
Previous studies demonstrated the strong relation between unloading and cross-
sectional area (CSA) reduction in both the acute [157] and sub-acute [24] phase of 
SCI. Moreover, myostatin mRNA expression has been investigated in different 
conditions like HIV and chronic stroke, showing a significative increase compared to 
healthy subjects. However, as previously said, at present time there are no study in 
literature investigating the serum myostatin concentration in SCI patients  and only 
few studies, with contrasting results, investigated this issue on animal models 
[73,183]. At present time only one study investigated myostatin mRNA expression in 
muscular biopsies obtained from chronic SCI patients, reporting a reduction of 46% 
compared to healthy subjects. However the authors didn’t find a statistical difference 
regarding myostatin concentration measured using the Western Blot method [47]. 
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The main difference with this work lies  in the fact that authors measured myostatin 
expression and concentration at muscular microenviromnment level, while no 
investigation about myostatin serum concentrations have been performed. Thus the 
differences found by Leger et al. regarding myostatin concentration and expression 
at local level could not reflect those at circulating level. With our data we integrate 
these molecular data, showing that myostatin concentration is  increased in SCI 
patients even at systemic level if compared to healthy controls, and this difference is 
similar in both complete and incomplete patients. Moreover, Leger et al. enrolled a 
smaller sample than ours, and the time from lesion ranged from 3 months to 30 
years, while in this  study only patients 24 months from SCI have been enrolled. This 
could lead to a enrollment bias, putting on the same level acute patients and chronic 
patients, considering that Castro et al. previously observed a peak of skeletal muscle 
mass reduction only 6 months after SCI [24].
In conclusion, being myostatin pathway inhibition a key target to facilitate muscle 
growth, data reported in this work support the hypothesis that myostatin could be a 
possible biomarker to monitor the evolution of muscular modifications in SCI patients 
and the impact of a potential therapeutical treatment targeting this pathway.
Sclerostin
In this study SCI patients, both complete and incomplete, showed statistically 
significant higher values of serum sclerostin compared to healthy subjects. Our 
results are somehow in contrast with those reported in the only study available in 
literature, in which serum sclerostin levels have been investigated in SCI patients 
[167]. Thus, Morse et al. proposed a model in which serum sclerostin is increased in 
the acute and sub-acute phase (up to 6 months) after SCI and even reduced in the 
chronic phase compared to healthy controls [167]. Compared to this study, Morse et. 
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al. enrolled a larger population, but considering the complete SCI subgroup only, the 
population numerosity was similar. However the population of this studie is  different 
and non comparable, regarding both age of SCI (40.5y vs 55.8y) and time from 
lesion (8y vs 22y). Moreover our study population was  more homogeneous regarding 
both age and time from lesion. Lastly, even the age of control group was different in 
the two studies r (28.3 vs 61.7). These are relevant differences between the work 
published by Morse and this  study considering that sclerostin has been demonstrated 
to increase with age [184]. Thus, in light of these considerations, the differences 
found by our group with the model proposed by Morse et al. could lie in the different 
age of patients enrolled regarding both SCI and control group. This  could have 
important consequences in light of potential therapeutical options targeting sclerostin 
pathway. Thus Morse et al. [167], based on the literature supporting emerging 
therapeutic trials  [185-187], suggested that treatment with an anti-sclerostin antibody 
would be ineffective in chronic SCI because they showed that in this condition 
sclerostin levels already are suppressed. This  suggests that the sclerostin pathway 
should be targeted immediately after SCI; however, with our findings, we suggest that 
anti-sclerostin antibodies could be a therapeutic option even in chronic SCI, because 
serum sclerostin levels are still high in this phase, like in the acute one. 
Bone Mineral Density (BMD)
In this study SCI patients  showed statistically significant lower values of BMD than 
healthy controls. This difference was present in both complete and incomplete 
patients, with a lesser magnitude in the second subgroup. Our data are similar to 
those previously obtained by Warden et al. [188] with ultrasound technique and 
regarding the differences between the two subgroups with the work of Jiang et al. 
[155].
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DXA measurement of BMD is the gold standard for the diagnosis of osteoporosis 
[189]. However, as previously noticed, this technique could not be so easy to perform 
in SCI patients because of their severe motor impariments, factors limiting correct 
scan positioning (contractures, spasms, and amputation) or the presence of scan 
artifacts due to heterotopic ossification, artificial joints, or metal rods. Moreover 
fracture risk prediction by bone density category after SCI has not well been defined 
yet and fractures are most common at distal sites (knee and tibia) which are not 
routinely included in standard clinical DXA scans.
For these reasons BMD evaluation could be of little clinical utility in SCI patients, 
thus, we choose to measure it with heel quantitative ultrasound tecnique, being 
easier (SCI patients  can stay on the wheelchair during measurement) and faster 
compared to DXA. Lastly, quantitative ultrasound tecnique has robust evidences 
supporting its  reproducibility and correlation with osteoporotic fracture risk at both 
vertebral and femoral site [158,190-192]. 
Correlations
Muscle tissue could be considered both an endocrine and paracrine organ, able to 
produce many cytokines, called “myokines” (i.e. Il-6,8,15), after different stimuli like 
contraction [81-83]. These factors are emerging as  key modulators  of glucose and fat 
metabolism and of the general responses to physical activity [84-86]. Similarly, it has 
been widely demonstrated that bone tissue has some important endocrine functions 
apart from the classic ones like architectural activity and mineral metabolisms, and 
this  endocrine activity is  sustained by osteocytes and sclerostin, which are able to up 
or down-regulate bone remodelling in response to mechanichal load [87,88]. 
However only in the few years  it has  been hypothesized that bone and muscle could 
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be functionally related not only for proximity aspects but also through a biochemical 
crosstalk sustained by these secreted factors.
As emerges in Figure 5, the only variable correlating with serum myostatin is  serum 
sclerostin (r2 0.42; p = 0.0012). We choose to perform the correlation only in the SCI 
complete group because of the low numerosity of the incomplete group. Our data 
about this correlation between sclerostin and myostatin should be taken cautiosly, 
considering the low numerosity of the sample. However, assuming the hypothesis of 
a biochemical crosstalk between bone and muscle tissue, which could explain maybe 
in part the pathophysiological mechanisms underlying the peculiar modifications 
observed in these two tissues after SCI, myostatin could be one of the responsible of 
this  crosstalk, by the muscle side. However this remain just an hypothesis and further 
studies are needed to investigate deeply this possible crosstalk, in which other 
mediators could be involved.
Other serum variables
Regarding 25(OH)D modifications we confirmed previous data obtained in larger 
studies [193-196], showing that worse SCI impairment is related with an increased 
prevalence of severe hypovitaminosis D. Interestingly, IGF-I serum levels were lower 
in SCI compared to healthy controls. However the lack of significancy in this 
comparison leads to the consideration that circulating modifications in IGF-I 
concentrations are not reflecting the modifications at muscle and bone 
microenvironmental level in SCI patients. 
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Study limitations
This  study has some limitations. The first regards  the relatively small sample size. 
However this is a common issue in studies  on SCI patients, because of the low 
incidence of this pathology and the different characteristics between the different 
phases after the spinal lesion (acute, sub-acute and chronic) that furtherly divide this 
pathology in three totally different conditions. Another limit of this study lies in the 
absence of data about the muscle microenvironment to correlate with those obtained 
at circulating level. 
Lastly our data are not correlated with a specifical imaging technique to quantifiy 
muscular modifications  in SCI patients (i.e. Appendicular DXA or MRI scans), 
however, considering that this is the first study investigating serum myostatin 
concentrations in SCI patients, our primary outcome was to assess only the presence 
of differences in this  variable serum concentrations between SCI patients and healthy 
controls.
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FUTURE PERSPECTIVES
A future development of this  study could be related to a deeper investigation of COX 
and PGE2 pathway, analyzing by immunoistochemistry the localization of COX-1,2 
and EP1,2 in muscle tissue obtained from SCI patients  and healthy controls in 
relation to muscle fiber type (I and II).
Moreover, in light of the results obtained in this study, the supposed role of sclerostin 
and myostatin in the bone and muscle biochemical crosstalk could be furtherly 
expanded by a larger study involving also more sophisticated imaging techniques like 
MRI scan for muscular CSA evaluation and fat infiltration.
Lastly, in light of this study results  and considering that at present time monoclonal 
antibodies against myostatin for therapeutical purposes are in phase II studies, 
myostatin pathway could be an interesting candidate from a therapeutical point of 
view to prevent the muscular modifications in the acute and sub-acute phase after 
SCI.
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CONCLUSIONS
Translational aspects of the thesis
Usually, the term Translational Medicine refers to the “bench-to-bedside” enterprise 
of harnessing knowledge from basic sciences to produce new drugs, devices, and 
treatment options for patients. Thus, the end point of the interface between basic 
science and clinical medicine is  the production of a promising new treatment that can 
be used clinically or commercialized [197]. This  enterprise is vital, and has been 
characterized as follows: “effective translation of the new knowledge, mechanisms, 
and techniques generated by advances  in basic science research into new 
approaches for prevention, diagnosis, and treatment of disease is  essential for 
improving health” [198]. 
Following this idea, during the study design phase, every possible effort have been 
made in order to project a research plan capable to play attention both to molecular 
and clinical research. 
For this  reason, the first step was to develop a roadmap that, starting from a very 
serious issue affecting SCI subjects (severe muscular modifications), could, initially, 
provide a new efficient diagnostic method and subsequently to investigate the 
histological and molecular characteristics  of skeletal muscles of these patients. The 
goal of this  research is to add new information useful to the development of a new 
therapy based on the control of communication molecules that regulate muscular 
trophism and muscle-bone network. 
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Clinical and Molecular conclusions
Muscular modification in chronic SCI patients are a growing issue, considering their 
impact on comorbidity risk factors (i.e. diabetes, obesity, lipid disorders, 
cardiovascular disease) in these patients  and the overall disability and health care 
costs [142,199]. However, in contrast with bone tissue modifications, this  issue has 
been little analyzed and the pathological mechanisms determing these modifications 
at muscle level after SCI are still under investigation.
In this study, according to the previous  hypothesis  of a biochemical more than 
functional relationship between bone and muscle, we showed that serum myostatin, 
a powerful inhibitor of muscle proliferation selectively produced by satellite cells, is 
significantly higher in chronic SCI patients compared to healthy controls. Moreover 
we confirmed the previously published data about increased serum sclerostin in SCI 
patients, finding also a correlation between serum sclerostin and myostatin. Thus we 
gave further evidences of the hypothesized biochemical crosstalk involving 
osteocytes and sclerostin from the bone side and satellite cells  and myostatin on the 
muscle side. The results obtained are encouraging, suggesting myostatin as a 
potential biomarker of muscular modifications and a potential therapeutical target to 
prevent them not only in SCI patients but also in other pathological unloading 
conditions.
Regarding the muscle biopsy phase of this  study, obtained results support the 
easiness, accuracy and low complication rate of a mini-invasive percutaneous tri-
axial end cut needle biopsy in skeletal muscle of both SCI patients and healthy 
controls. This technique could be a useful tool, even for definitive diagnosis, in 
conditions like malignancies, in which the overall quantity of specimen to perform a 
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citological or molecular analysis  is really small. Similarly, this technique, could be 
suitable for research purposes, to perform molecular analysis, even in benign 
conditions. However, for histological diagnostic purposes and/or conditions in which 
the original tissue is  already pathologically modified, like skeletal muscle in SCI, this 
technique could not be the most appropriate and should be integrated with more 
invasive core biopsy techniques.
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